Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free INTS Stock Alerts

Intensity Therapeutics (INTS) Financials

Intensity Therapeutics logo
$4.70 -0.05 (-1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$4.58 -0.13 (-2.66%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Intensity Therapeutics

Annual Income Statements for Intensity Therapeutics

This table shows Intensity Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.58 -12 -16 -12
Consolidated Net Income / (Loss)		 -7.58 -11 -16 -12
Net Income / (Loss) Continuing Operations		 -7.58 -11 -16 -12
Total Pre-Tax Income 		-7.63 -11 -16 -12
Total Operating Income		 -7.55 -8.32 -17 -12
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 7.55 8.32 17 12
Selling, General & Admin Expense		 2.42 3.53 6.09 5.19
Research & Development Expense		 5.13 4.79 10 6.79
Total Other Income / (Expense), net		 -0.08 -2.24 0.32 0.37
Interest & Investment Income		 0.00 0.32 0.31 0.18
Other Income / (Expense), net		 - - 0.00 0.19
Basic Earnings per Share		 ($2.22) ($1.38) ($29.24) ($8.56)
Weighted Average Basic Shares Outstanding		 3.41M 8.62M 556.28K 1.36M
Diluted Earnings per Share		 ($2.22) ($1.38) ($29.24) ($8.56)
Weighted Average Diluted Shares Outstanding		 3.41M 8.62M 556.28K 1.36M
Weighted Average Basic & Diluted Shares Outstanding		 - 13.71M 15.18M 2.54M

Quarterly Income Statements for Intensity Therapeutics

This table shows Intensity Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.33 -3.17 -4.60 -4.97 -3.51 -3.18 -3.35 -2.54 -2.67 -3.05 -2.43
Consolidated Net Income / (Loss)		 -2.33 -3.17 -4.60 -4.97 -3.51 -3.18 -3.35 -2.54 -2.67 -3.05 -2.43
Net Income / (Loss) Continuing Operations		 -2.33 -3.17 -4.60 -4.97 -3.51 -3.18 -3.35 -2.54 -2.67 -3.05 -2.43
Total Pre-Tax Income 		-2.33 -3.20 -4.60 -4.97 -3.51 -3.18 -3.35 -2.54 -2.67 -3.05 -2.43
Total Operating Income		 -2.49 -3.35 -4.74 -5.07 -3.57 -3.20 -3.39 -2.71 -2.73 -3.14 -2.53
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 2.49 3.35 4.74 5.07 3.57 3.20 3.39 2.71 2.73 3.14 2.53
Selling, General & Admin Expense		 1.14 1.55 1.93 1.51 1.42 1.24 1.21 1.16 1.18 1.64 1.33
Research & Development Expense		 1.35 1.80 2.82 3.56 2.15 1.97 2.19 1.54 1.55 1.50 1.20
Total Other Income / (Expense), net		 0.16 0.16 0.14 0.10 0.06 0.02 0.05 0.17 0.06 0.09 0.09
Interest & Investment Income		 0.15 0.18 0.14 0.10 0.05 0.03 0.02 0.02 0.06 0.09 0.09
Other Income / (Expense), net		 0.01 - 0.00 0.00 0.01 -0.01 0.03 0.15 0.00 - -0.00
Basic Earnings per Share		 ($0.17) $0.61 ($0.34) ($0.36) ($0.25) ($5.72) ($5.51) ($0.13) ($0.06) ($2.25) ($0.96)
Weighted Average Basic Shares Outstanding		 13.66M 8.62M 13.71M 13.71M 13.80M 556.28K 606.93K 18.87M 43.04M 1.36M 2.53M
Diluted Earnings per Share		 ($0.17) $0.61 ($0.34) ($0.36) ($0.25) ($5.72) ($5.51) ($0.13) ($0.06) ($2.25) ($0.96)
Weighted Average Diluted Shares Outstanding		 13.66M 8.62M 13.71M 13.71M 13.80M 556.28K 606.93K 18.87M 43.04M 1.36M 2.53M
Weighted Average Basic & Diluted Shares Outstanding		 13.71M 13.71M 13.71M 13.77M 13.87M 15.18M 18.40M 47.06M 60.06M 2.54M 2.70M

Annual Cash Flow Statements for Intensity Therapeutics

This table details how cash moves in and out of Intensity Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.23 7.24 -5.97 9.33
Net Cash From Operating Activities		 -5.48 -7.21 -15 -9.23
Net Cash From Continuing Operating Activities		 -5.48 -7.21 -15 -9.23
Net Income / (Loss) Continuing Operations		 -7.58 -11 -16 -12
Consolidated Net Income / (Loss)		 -7.58 -11 -16 -12
Non-Cash Adjustments To Reconcile Net Income		 1.17 3.81 3.02 2.03
Changes in Operating Assets and Liabilities, net		 0.76 -0.63 -2.10 0.35
Net Cash From Investing Activities		 0.00 -6.02 6.35 0.00
Net Cash From Continuing Investing Activities		 0.00 -6.02 6.35 0.00
Purchase of Investments		 0.00 -15 -3.06 0.00
Sale and/or Maturity of Investments		 0.00 9.03 9.41 0.00
Net Cash From Financing Activities		 2.25 20 2.90 19
Net Cash From Continuing Financing Activities		 2.25 20 2.90 19
Repurchase of Common Equity		 0.00 0.00 -0.65 -1.82
Issuance of Common Equity		 0.00 22 3.55 20

Quarterly Cash Flow Statements for Intensity Therapeutics

This table details how cash moves in and out of Intensity Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 6.56 1.86 -1.10 -4.22 -0.46 -0.19 -1.66 1.29 4.85 4.85 -1.68
Net Cash From Operating Activities		 -5.12 -0.95 -4.37 -4.21 -3.97 -2.67 -1.99 -2.46 -2.39 -2.40 -1.83
Net Cash From Continuing Operating Activities		 -5.12 -0.95 -4.37 -4.21 -3.97 -2.80 -1.99 -2.46 -2.39 -2.40 -1.83
Net Income / (Loss) Continuing Operations		 -2.33 -3.17 -4.60 -4.97 -3.51 -3.18 -3.35 -2.54 -2.67 -3.05 -2.43
Consolidated Net Income / (Loss)		 -2.33 -3.17 -4.60 -4.97 -3.51 -3.18 -3.35 -2.54 -2.67 -3.05 -2.43
Amortization Expense		 - - 0.01 - - - 0.01 - - - 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.35 0.43 1.16 0.60 0.52 0.75 0.44 0.66 0.48 0.46 0.39
Changes in Operating Assets and Liabilities, net		 -3.14 1.80 -0.92 0.16 -0.97 -0.36 0.92 -0.57 -0.19 0.19 0.21
Net Cash From Investing Activities		 -8.84 2.82 3.26 -0.01 3.10 - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 -8.84 2.82 3.26 -0.01 3.10 - 0.00 - - - 0.00
Net Cash From Financing Activities		 21 -0.01 0.01 0.00 0.41 2.48 0.33 3.74 7.24 7.26 0.15
Net Cash From Continuing Financing Activities		 21 -0.01 0.01 0.00 0.41 2.48 0.33 3.74 7.24 7.26 0.15
Repurchase of Common Equity		 - - 0.00 - -0.08 -0.57 -0.02 -0.93 -0.30 -0.57 -0.01
Issuance of Common Equity		 22 - 0.01 0.00 0.50 3.05 0.35 4.68 7.54 7.82 0.16

Annual Balance Sheets for Intensity Therapeutics

This table presents Intensity Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.76 17 4.78 14
Total Current Assets		 1.45 15 3.36 13
Cash & Equivalents		 1.31 8.56 2.59 12
Prepaid Expenses		 0.06 0.69 0.77 0.79
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.31 1.83 1.42 1.39
Other Noncurrent Operating Assets		 0.31 1.83 1.42 1.39
Total Liabilities & Shareholders' Equity		 1.76 17 4.78 14
Total Liabilities		 6.86 4.13 1.87 2.23
Total Current Liabilities		 6.82 3.96 1.76 2.15
Accounts Payable		 0.60 3.05 1.22 0.58
Accrued Expenses		 1.72 0.89 0.51 1.53
Other Current Liabilities		 4.49 0.02 0.03 0.03
Total Noncurrent Liabilities		 0.04 0.17 0.11 0.08
Other Noncurrent Operating Liabilities		 0.04 0.17 0.11 0.08
Total Equity & Noncontrolling Interests		 -15 13 2.92 12
Total Preferred & Common Equity		 -15 13 2.92 12
Preferred Stock		 0.00 0.00 0.00 0.00
Total Common Equity		 -15 13 2.92 12
Common Stock		 24 64 70 90
Retained Earnings		 -39 -51 -67 -78
Other Equity Adjustments		 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for Intensity Therapeutics

This table presents Intensity Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 17 12 8.67 5.21 3.07 4.44 9.59 12
Total Current Assets		 17 11 7.44 3.79 1.65 3.04 8.19 11
Cash & Equivalents		 6.69 7.46 3.24 2.78 0.93 2.22 7.07 10
Prepaid Expenses		 0.97 0.67 1.12 1.01 0.72 0.82 1.12 0.66
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.18 1.24 1.23 1.43 1.41 1.41 1.40 1.39
Other Noncurrent Operating Assets		 0.18 1.24 1.23 1.43 1.41 1.41 1.40 1.39
Total Liabilities & Shareholders' Equity		 17 12 8.67 5.21 3.07 4.44 9.59 12
Total Liabilities		 0.90 2.69 3.33 2.43 2.73 2.26 2.36 2.31
Total Current Liabilities		 0.72 2.52 3.20 2.32 2.63 2.16 2.28 2.24
Accounts Payable		 0.36 1.22 1.92 0.54 1.59 1.19 1.68 0.64
Accrued Expenses		 0.36 1.27 1.26 1.75 1.01 0.94 0.56 1.57
Other Current Liabilities		 0.01 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Total Noncurrent Liabilities		 0.18 0.17 0.12 0.12 0.10 0.10 0.09 0.07
Other Noncurrent Operating Liabilities		 0.18 0.17 0.12 0.12 0.10 0.10 0.09 0.07
Commitments & Contingencies		 - - - - - - - 0.00
Total Equity & Noncontrolling Interests		 16 9.72 5.35 2.78 0.33 2.18 7.22 9.98
Total Preferred & Common Equity		 16 9.72 5.35 2.78 0.33 2.18 7.22 9.98
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 16 9.72 5.35 2.78 0.33 2.18 7.22 9.98
Common Stock		 63 65 65 66 70 75 83 91
Retained Earnings		 -47 -55 -60 -64 -70 -73 -75 -81

Annual Metrics And Ratios for Intensity Therapeutics

This table displays calculated financial ratios and metrics derived from Intensity Therapeutics' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 13,709,377.00 13,867,697.00 60,064,965.00
DEI Adjusted Shares Outstanding		 0.00 13,709,377.00 554,708.00 2,402,599.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.87 -29.33 -4.83
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -10.70% -103.21% 28.92%
EBIT Growth		 0.00% -10.19% -99.33% 28.92%
NOPAT Growth		 0.00% -10.19% -99.36% 27.81%
Net Income Growth		 0.00% -38.99% -54.37% 28.66%
EPS Growth		 0.00% 37.84% -54.37% 28.66%
Operating Cash Flow Growth		 0.00% -31.55% -111.24% 39.34%
Free Cash Flow Firm Growth		 0.00% 0.00% -27.61% 40.91%
Invested Capital Growth		 0.00% 74.82% 120.32% -113.72%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.91% 0.58%
EBIT Q/Q Growth		 0.00% 0.00% 0.91% 0.58%
NOPAT Q/Q Growth		 0.00% 0.00% 0.90% 0.52%
Net Income Q/Q Growth		 0.00% 0.00% -0.06% 1.11%
EPS Q/Q Growth		 0.00% 0.00% -0.06% 1.11%
Operating Cash Flow Q/Q Growth		 0.00% 8.72% -12.76% 2.81%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.70%
Invested Capital Q/Q Growth		 0.00% 0.00% 11,033.33% -129.03%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.37% 99.77% 100.00% 100.00%
Interest Burden Percent		 101.06% 126.96% 98.11% 98.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 148.73% -261.36% -202.34% -156.90%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -4,131.55% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 440.46% 62.75% -202.34% -156.90%
Return on Equity Simple (ROE_SIMPLE)		 50.22% -80.06% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.29 -5.82 -12 -8.38
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -175.08% -58.61% -53.65% -44.46%
Return On Investment Capital (ROIC_SIMPLE)		 - -44.24% -397.86% -70.57%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -7.55 -8.32 -17 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.37 -8.16 -17 -12
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 8.93 8.36 2.07
Price to Tangible Book Value (P/TBV)		 0.00 8.93 8.36 2.07
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 66.52 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 0.26 -2.00 -1.08 -0.98
Leverage Ratio		 -0.34 2.36 1.37 1.28
Compound Leverage Factor		 -0.35 3.00 1.35 1.26
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -196.16% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 296.16% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 -46.94 12.18 -22.73 -3.00
Noncontrolling Interest Sharing Ratio		 -196.16% 124.01% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.21 3.91 1.92 5.92
Quick Ratio		 0.19 3.73 1.48 5.56
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -11 -14 -8.01
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -4.14 0.00 0.00
Operating Cash Flow to Interest Expense		 -66.79 -2.81 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -66.79 -2.81 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 -6.41 -1.61 0.33 -0.05
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 4.80 1.94 -0.37
Enterprise Value (EV)		 28 103 22 13
Market Capitalization		 20 117 24 25
Book Value per Share		 ($4.43) $0.96 $0.21 $0.20
Tangible Book Value per Share		 ($4.43) $0.96 $0.21 $0.20
Total Capital		 -5.10 13 2.92 12
Total Debt		 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -1.31 -15 -2.59 -12
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.68 -3.27 -0.98 -1.36
Debt-free Net Working Capital (DFNWC)		 -5.37 12 1.61 11
Net Working Capital (NWC)		 -5.37 12 1.61 11
Net Nonoperating Expense (NNE)		 2.30 4.71 4.66 3.23
Net Nonoperating Obligations (NNO)		 -1.31 -15 -2.59 -12
Total Depreciation and Amortization (D&A)		 0.18 0.16 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.38) ($29.25) ($8.56)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 8.62M 556.28K 1.36M
Adjusted Diluted Earnings per Share		 $0.00 ($1.38) ($29.25) ($8.56)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 8.62M 556.28K 1.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.71M 607.24K 2.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.29 -5.82 -12 -8.38
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -92.07 -3.24 0.00 0.00
NOPAT to Interest Expense		 -64.45 -2.27 0.00 0.00
EBIT Less CapEx to Interest Expense		 -92.07 -3.24 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -64.45 -2.27 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -4.01% -15.65%

Quarterly Metrics And Ratios for Intensity Therapeutics

This table displays calculated financial ratios and metrics derived from Intensity Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 27,368,754.00 13,709,377.00 13,709,377.00 13,711,877.00 13,771,852.00 13,867,697.00 15,180,945.00 18,398,202.00 47,057,727.00 60,064,965.00 2,540,518.00
DEI Adjusted Shares Outstanding		 27,368,754.00 13,709,377.00 13,709,377.00 13,711,877.00 13,771,852.00 554,708.00 607,238.00 18,398,202.00 47,057,727.00 2,402,599.00 2,540,518.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.09 -0.23 -0.34 -0.36 -0.26 -5.73 -5.51 -0.14 -0.06 -1.27 -0.96
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -33.94% 0.00% -282.02% -373.30% -43.76% 4.29% 29.15% 49.62% 23.34% 2.15% 24.88%
EBIT Growth		 -40.68% 0.00% -278.53% -316.52% -43.76% 4.29% 29.12% 49.62% 23.34% 2.15% 24.81%
NOPAT Growth		 -40.91% 0.00% -278.23% -315.15% -43.32% 4.47% 28.44% 46.64% 23.45% 1.97% 25.57%
Net Income Growth		 -31.22% 0.00% -244.54% -34.32% -50.84% -0.28% 27.29% 48.96% 23.97% 4.09% 27.28%
EPS Growth		 0.00% 0.00% 12.82% 74.83% -47.06% -0.28% 27.29% 63.89% 76.00% 4.09% 82.58%
Operating Cash Flow Growth		 -399.09% 42.12% -384.57% -1,663.18% 22.41% -182.03% 54.44% 41.72% 39.90% 10.01% 8.20%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 178.40% -11.40% 0.00% -0.42% -122.85% 7.30% 56.38% 17.94%
Invested Capital Growth		 0.00% 0.00% 0.00% -106.53% -101.15% 120.32% 23.23% 96.73% 5,266.67% -113.72% 55.29%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -131.28% -35.37% -41.28% -7.01% 29.75% 9.88% -4.58% 23.90% -6.89% -15.02% 19.71%
EBIT Q/Q Growth		 -103.53% -35.37% -41.46% -6.87% 29.75% 9.88% -4.77% 24.03% -6.89% -15.02% 19.49%
NOPAT Q/Q Growth		 -104.01% -34.60% -41.46% -6.87% 29.57% 10.28% -5.96% 20.30% -1.04% -14.89% 19.55%
Net Income Q/Q Growth		 37.07% -36.20% -45.11% -7.99% 29.33% 9.45% -5.22% 24.20% -5.28% -14.23% 20.22%
EPS Q/Q Growth		 88.11% 458.82% -155.74% -5.88% 30.56% 9.45% -5.22% 40.91% 53.85% -14.23% 57.33%
Operating Cash Flow Q/Q Growth		 -2,041.84% 81.52% -361.52% 3.48% 5.74% 32.83% 25.45% -23.48% 2.81% -0.59% 23.95%
Free Cash Flow Firm Q/Q Growth		 87.35% 100.00% 0.00% 588.33% -117.98% -87.27% 38.92% -11.14% 27.09% 11.88% -14.92%
Invested Capital Q/Q Growth		 -98.25% -716.52% 51.98% -26.32% 99.69% 11,033.33% -281.40% 94.62% 584.38% -129.03% -491.11%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.25% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 94.03% 95.32% 97.05% 98.07% 98.65% 99.13% 99.55% 99.33% 97.84% 97.17% 96.28%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -261.36% -142.00% -147.23% -173.99% -202.34% -298.57% -334.12% -234.70% -156.90% -207.37%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -4,131.55% 0.00% 0.00% -5,537.10% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 62.75% -142.00% -147.23% -173.99% -202.34% -298.57% -334.12% -234.70% -156.90% -207.37%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -142.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.74 -2.35 -3.32 -3.55 -2.50 -2.24 -2.38 -1.89 -1.91 -2.20 -1.77
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.48% -5.58% -24.44% -44.05% -11.00% -10.81% -17.00% -15.07% -15.39% -11.76% -11.92%
Return On Investment Capital (ROIC_SIMPLE)		 - -17.83% -34.15% -66.39% -89.92% -76.84% -711.32% -86.70% -26.49% -18.51% -17.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.48 -3.35 -4.74 -5.07 -3.56 -3.21 -3.36 -2.55 -2.73 -3.14 -2.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.48 -3.35 -4.74 -5.07 -3.56 -3.21 -3.36 -2.55 -2.73 -3.14 -2.52
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.41 8.93 7.33 12.57 18.93 8.36 89.54 2.59 1.58 2.07 1.50
Price to Tangible Book Value (P/TBV)		 3.41 8.93 7.33 12.57 18.93 8.36 89.54 2.59 1.58 2.07 1.50
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 147.74 0.00 0.00 0.00 0.00 66.52 0.00 0.00 28.09 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -1.12 -1.08 -0.32 -0.99 -1.08 -1.14 -1.13 -0.98 -0.98 -1.08
Leverage Ratio		 1.06 2.36 1.28 1.31 1.18 1.37 1.54 1.74 1.48 1.28 1.49
Compound Leverage Factor		 0.99 2.25 1.24 1.29 1.16 1.36 1.53 1.73 1.45 1.24 1.43
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 13.13 9.28 1.07 -6.03 -13.51 -29.47 -23.06 -8.30 -0.97 -5.16
Noncontrolling Interest Sharing Ratio		 0.00% 124.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 22.98 3.91 4.43 2.32 1.63 1.92 0.63 1.40 3.60 5.92 4.86
Quick Ratio		 21.62 3.73 4.17 1.97 1.20 1.48 0.35 1.02 3.11 5.56 4.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.01 0.00 -2.55 12 -2.23 -4.18 -2.56 -2.84 -2.07 -1.83 -2.10
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.26 -1.61 -0.78 -0.98 -0.00 0.33 -0.60 -0.03 0.16 -0.05 -0.27
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.26 0.00 -0.78 -16 -0.26 1.94 0.18 0.95 0.16 -0.37 0.33
Enterprise Value (EV)		 39 103 61 61 50 22 29 3.43 4.35 13 4.69
Market Capitalization		 54 117 71 67 53 24 30 5.65 11 25 15
Book Value per Share		 $1.16 $0.96 $0.71 $0.39 $0.20 $0.21 $0.02 $0.12 $0.15 $0.20 $3.93
Tangible Book Value per Share		 $1.16 $0.96 $0.71 $0.39 $0.20 $0.21 $0.02 $0.12 $0.15 $0.20 $3.93
Total Capital		 16 13 9.72 5.35 2.78 2.92 0.33 2.18 7.22 12 9.98
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -16 -15 -10 -6.32 -2.78 -2.59 -0.93 -2.22 -7.07 -12 -10
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.26 -3.27 -1.85 -2.09 -1.31 -0.98 -1.91 -1.34 -1.16 -1.36 -1.58
Debt-free Net Working Capital (DFNWC)		 16 12 8.65 4.24 1.47 1.61 -0.98 0.87 5.91 11 8.66
Net Working Capital (NWC)		 16 12 8.65 4.24 1.47 1.61 -0.98 0.87 5.91 11 8.66
Net Nonoperating Expense (NNE)		 0.59 0.82 1.28 1.42 1.01 0.94 0.97 0.64 0.76 0.85 0.67
Net Nonoperating Obligations (NNO)		 -16 -15 -10 -6.32 -2.78 -2.59 -0.93 -2.22 -7.07 -12 -10
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) $0.61 ($0.34) ($0.36) ($0.25) ($143.00) ($5.50) ($0.13) ($0.06) ($56.25) ($0.96)
Adjusted Weighted Average Basic Shares Outstanding		 13.66M 8.62M 13.71M 13.71M 13.80M 22.25K 606.93K 18.87M 43.04M 54.25K 2.53M
Adjusted Diluted Earnings per Share		 $0.00 $0.61 ($0.34) ($0.36) ($0.25) ($143.00) ($5.50) ($0.13) ($0.06) ($56.25) ($0.96)
Adjusted Weighted Average Diluted Shares Outstanding		 13.71M 8.62M 13.71M 13.71M 13.80M 22.25K 606.93K 18.87M 43.04M 54.25K 2.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($143.00) $0.00 $0.00 $0.00 ($56.25) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.71M 13.71M 13.71M 13.77M 13.87M 607.24K 735.93K 47.06M 60.06M 101.62K 2.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.74 -2.35 -3.32 -3.55 -2.50 -2.24 -2.38 -1.89 -1.91 -2.20 -1.77
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -0.50% -4.01% -4.46% -12.74% -15.52% -15.65% -16.89%

Financials Breakdown Chart

Key Financial Trends

Intensity Therapeutics (NASDAQ: INTS) remains a pre-revenue biotech with a balance sheet and cash burn profile that are more important than traditional profitability metrics. Over the last several quarters, the company has continued to spend heavily on research and development while offsetting losses with periodic equity financing. The latest quarter shows some improvement in cash usage and a stronger cash position, but dilution remains a major theme for shareholders.

  • Cash improved sharply in Q1 2026: cash and equivalents rose to $10.2 million from $7.1 million in Q3 2025 and $2.2 million in Q2 2025, indicating the company boosted liquidity after earlier funding.
  • Operating cash burn narrowed: net cash used in operations was $1.83 million in Q1 2026, better than $2.40 million in Q4 2025 and slightly improved from $2.39 million in Q3 2025.
  • Net loss improved year over year in the latest quarter: Q1 2026 net loss was $2.43 million, narrower than $3.05 million in Q4 2025 and $2.67 million in Q3 2025.
  • Interest income helped offset losses: the company generated $94,000 in interest and investment income in Q1 2026, which slightly reduced the quarterly pre-tax loss.
  • Debt appears minimal: the balance sheet shows only $70,000 in noncurrent liabilities and no meaningful long-term debt, which reduces financial leverage risk.
  • Liquidity is still adequate for now: total current assets of $10.9 million versus total current liabilities of $2.24 million gives the company a solid current ratio on paper.
  • The business is still pre-revenue: revenue was $0 in every quarter provided, so the company remains dependent on capital markets and future clinical progress.
  • Research spending remains elevated: R&D expense was $1.20 million in Q1 2026, down from prior quarters but still the main driver of losses.
  • Share dilution has been significant: weighted average shares rose dramatically over the period, reflecting repeated equity issuance to fund operations.
  • Historical cash usage has been heavy: operating cash outflows were consistently large in 2024 and 2025, including $4.37 million in Q1 2024 and $4.21 million in Q2 2024.
  • Retained earnings remain deeply negative: retained earnings were $(80.8) million at the end of Q1 2026, underscoring the company’s long history of losses.
  • Equity financing remains a key dependency: financing cash inflows were positive in recent quarters, including $150,000 in Q1 2026 and much larger amounts earlier, showing the company still leans on external capital to stay funded.

Bottom line: INTS is showing some short-term progress on cash preservation and a better liquidity position, but the core story is unchanged: it is a development-stage biotech with no revenue, ongoing operating losses, and meaningful dilution risk. For investors, the biggest catalysts will likely come from clinical or regulatory milestones rather than current financial performance.

07/20/26 08:43 PM ETAI Generated. May Contain Errors.

Intensity Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Intensity Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Intensity Therapeutics' net income appears to be on an upward trend, with a most recent value of -$11.61 million in 2025, rising from -$7.58 million in 2022. The previous period was -$16.27 million in 2024. Find out what analysts predict for Intensity Therapeutics in the coming months.

Intensity Therapeutics' total operating income in 2025 was -$11.97 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.97 million

Over the last 3 years, Intensity Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2025, a change of 0.0%.

Intensity Therapeutics' total liabilities were at $2.23 million at the end of 2025, a 19.3% increase from 2024, and a 67.5% decrease since 2022.

In the past 3 years, Intensity Therapeutics' cash and equivalents has ranged from $1.31 million in 2022 to $11.92 million in 2025, and is currently $11.92 million as of their latest financial filing in 2025.

Over the last 3 years, Intensity Therapeutics' book value per share changed from -4.43 in 2022 to 0.20 in 2025, a change of -104.5%.


Related Companies

Financial statements for NASDAQ:INTS last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Backed Company Could Save Power Grid
A small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
NVIDIA offered $40B. The answer was no.
Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...
Behind the Markets | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
Trump is positioned. Elon lights the fuse.
Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...
Crypto 101 Media | Sponsoredtc pixel